BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Praluent (Alirocumab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Praluent (Alirocumab)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07477704-1033@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20261229
DTEND;VALUE=DATE:20261230
SUMMARY:Praluent (Alirocumab): Phase 2 readout est. (NCT07477704)
DESCRIPTION:Praluent (Alirocumab)\, phase 2\, Atherosclerotic Cardiovascula
 r Disease.\nStudy: A Study to See How Safe and Effective Alirocumab is Whe
 n Given Weekly to Adult Participants Who Have Hypercholesterolemia\nEstima
 ted primary completion: 29 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/alirocumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07477704
URL:https://assetmemo.bio/drug/alirocumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04781322-1033@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Praluent (Alirocumab): Phase 1 readout est. (NCT04781322)
DESCRIPTION:Praluent (Alirocumab)\, phase 1.\nStudy: Safety\, Tolerability\
 , and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers\nEs
 timated primary completion: 31 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/alirocumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT04781322
URL:https://assetmemo.bio/drug/alirocumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07581808-1033@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Praluent (Alirocumab): Phase 4 readout est. (NCT07581808)
DESCRIPTION:Praluent (Alirocumab)\, phase 4\, Atherosclerotic Cardiovascula
 r Disease.\nStudy: Dual PCSK9 Inhibition With Inclisiran and Alirocumab in
  Secondary Prevention\nEstimated primary completion: May 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/alirocumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07581808
URL:https://assetmemo.bio/drug/alirocumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06385262-1033@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Praluent (Alirocumab): Phase 2 readout est. (NCT06385262)
DESCRIPTION:Praluent (Alirocumab)\, phase 2.\nStudy: TOP 2301: Neoadjuvant 
 Chemo for NSCLC\nEstimated primary completion: 30 October 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/alirocumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06385262
URL:https://assetmemo.bio/drug/alirocumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07586540-1033@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Praluent (Alirocumab): Phase 3 readout est. (NCT07586540)
DESCRIPTION:Praluent (Alirocumab)\, phase 3.\nStudy: Alirocumab for Stabili
 sation of Symptomatic Vulnerable Carotid Plaque\nEstimated primary complet
 ion: March 2030. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/alir
 ocumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07586540
URL:https://assetmemo.bio/drug/alirocumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
